<h4>Background</h4>Mutations in the <i>TP53</i> gene and telomerase reverse transcriptase promoter (<i>TERT</i>p) are among the most frequent genetic alterations in bladder cancer, but the clinical impact of their co-occurrence has not been fully explored. The gene discussed is TP53; the disease is urinary bladder carcinoma.